Gene therapy for lipoprotein disorders

Bibliography

• PEARSON TA, BLAIR SN, DANIELS SR et al.: Al-TA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisery and Coordinating Committee. Circulation (2002) 106:388–391.
   Google Scholar
• KOZARSKY KF: Gene therapy for cardiovascular disease. Cuff. Opin. Pharmacol (2001) 1:197–202.
   PubMedGoogle Scholar
• •A review covering gene therapy for atherosclerosis, myocardial ischaemia and heart failure.
   Google Scholar
• THOMAS CE, EHRHARDT A. KAY MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. (2003) 4:346–358.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of viral genedelivery systems.
   Google Scholar
• MORSY MA, CASKEY CT: Expanded-capacity adenoviral vectors-the helper-dependent vectors. MoL Med. Today (1999) 5:18–24.
   PubMedGoogle Scholar
• BRUNZELL J, DEEB S: Familial lipoprotein lipase deficiency, ApoCII deficiency, and hepatic lipase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver C, Beaudet A, Sly W, Valle D (Eds), McGraw-Hill Inc, New York (2001):2789–2816.
   Google Scholar
• LIU G, ASHBOURNE-EXCOFFON KJ, WILSON JE et al: Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Hum. Gene Ther. (2000) 11:21–32.
   PubMed Web of Science ®Google Scholar
• EXCOFFON KJ, LIU G, MIAO L et al:Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2532–2539.
   PubMed Web of Science ®Google Scholar
• CHEN W, SRINIVASAN SR, ELKASABANY A, ELLS WORTH DL, BOERWINKLE E, BERENSON GS: Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: The Bogalusa Heart Study. Atherosclerosis (2001) 159:367–373.
   PubMed Web of Science ®Google Scholar
• CLEE S, LOUBSER O, COLLINS J, KASTELEIN JJ, HAYDEN MR: The
   Google Scholar
• •• LPLS447X cSNP is associated with decreased blood pressure, plasma triglycerides and risk of coronary artery disease. Clin. Genet. (2001) 60:293–300.
   PubMed Web of Science ®Google Scholar
• ROSS CJ, TWISK J, MEULENBERG JM et al.: Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally-occurring LPL(S447X) beneficial mutation. Hum. Gene Ther. (2004) 15:906–919.
   PubMed Web of Science ®Google Scholar
• NIERMAN MC, RIP J, TWISK J et al.: Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. Neth. J. Med. (2005) 63:14–20.
   PubMed Web of Science ®Google Scholar
• •This paper addresses the first clinical gene therapy trial for LPL deficiency.
   Google Scholar
• RADER DJ: Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm. Neth. J. Med. (2005) 63:2–3.
   PubMed Web of Science ®Google Scholar
• KOZARSKY KF, MCKINLEY DR, AUSTIN LL, RAPER SE, STRATFORD-PERRICAUDET LD, WILSON JM: In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. (1994) 269:13695–13702.
   PubMed Web of Science ®Google Scholar
• BROWN DR, BROUSSEAU ME, SHAMBUREK RD et al.: Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high density lipoproteins. Metabolism (1996) 45:1447–1457.
   PubMed Web of Science ®Google Scholar
• SHICHIRI M, TANAKA A, HIRATA Y: Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene complex. Gene Ther. (2003) 10:827–831.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI S, BROWN MS, GOLDSTEIN JL, GERARD RD, HAMMER RE, HERZ J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. (1993) 92:883–893.
   PubMed Web of Science ®Google Scholar
• KAWASHIRI M, ZHANG Y, USHER D, REILLY M, PURE E, RADER DJ: Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. (2001) 42:943–950.
   PubMed Web of Science ®Google Scholar
• LI J, FANG B, EISENSMITH RC et al.: In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J. Clin. Invest. (1995) 95:768–773.
   PubMed Web of Science ®Google Scholar
• YANG Y, ERTL HC, WILSON JM: MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity (1994) 1:433–442.
   PubMed Web of Science ®Google Scholar
• DAI Y, SCHWARTZ E, GU D, ZHANG W, SARVETNICK N, VERMA I: Cellular and humoral immune responses to adenoviral vectors containing Factor IX gene: tolerization of Factor IX and vector antigens allows for long-term expression. Proc. Natl Acad. Sci. USA (1995) 92:1401–1405.
   PubMed Web of Science ®Google Scholar
• KOZARSKY K, JOOSS K, DONAHEE M, STRAUSS J, WILSON JM: Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus mediated transfer of the VLDL receptor gene. Nat. Genet. (1996) 13:54–61.
   PubMed Web of Science ®Google Scholar
• JOOSS K, ERTL HC, WILSON JM: Cytotoxic T lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. (1998) 72:2945–2954.
   PubMed Web of Science ®Google Scholar
• CHEN SJ, RADER DJ, TAZELAAR J, KAWASHIRI M, GAO G, WILSON JM: Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mo/. Thee. (2000) 2:256–261.
   PubMed Web of Science ®Google Scholar
• TAKAHASI S, KAWARABAYASI Y, NAKAI T, SAKAI J, YAMAMOTO T: Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl Acad. Sci. USA (1992) 89:9252–9256.
   PubMed Web of Science ®Google Scholar
• OKA K, PASTORE L, KIM IH et al.: Lang-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation (2001) 103:1274–1281.
   PubMed Web of Science ®Google Scholar
• LEBHERZ C, GAO G, LOUBOUTIN JP, MILLAR J, RADER D, WILSON JM: Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. (2004) 6:663–672.
   PubMed Web of Science ®Google Scholar
• NOMURA S, MERCHED A. NOUR E, DIEKER C, OKA K, CHAN L: Law-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther. (2004) 11:1540–1548.
   PubMed Web of Science ®Google Scholar
• KANKKONEN HM, VAHAKANGAS E, MARR RA et al.: Lang-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mo/. Thee. (2004) 9:548–556.
   PubMed Web of Science ®Google Scholar
• GROSSMAN M, RADER DJ, MULLER DW et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. (1995) 1:1148–1154.
   PubMed Web of Science ®Google Scholar
• ••This paper reports the first clinical gene therapy trial for a lipid disorder (homozygous FH).
   Google Scholar
• SCHAEFER EJ, GREGG RE, GHISELLI G et al.: Familial apolipoprotein E deficiency. J. Clin. Invest. (1986) 78:1206–1219.
   PubMed Web of Science ®Google Scholar
• BRESLOW JL: Mouse models of atherosclerosis. Science (1996) 272:685–688.
   PubMed Web of Science ®Google Scholar
• STEVENSON S, MARSHALL-NEFF J, TENG B, LEE C, ROY S, MCCLELLAND A: Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler. Thromb. Vasc. Biol. (1995) 15:479–484.
   PubMed Web of Science ®Google Scholar
• KASHYAP VS, SANTAMARINA-FOJO S, BROWN DR et al.: Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J. Clin. Invest. (1995) 96:1612–1620.
   PubMed Web of Science ®Google Scholar
• TSUKAMOTO K, SMITH P, GLICK JM, RADER D: Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE-deficient mice. Clin. Invest. (1997) 100:107–114.
   Google Scholar
• DESURMONT C, CAILLAUD JM, EMMANUEL F et al.: Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler. Thromb. Vasc. Biol. (2000) 20:435–442.
   PubMed Web of Science ®Google Scholar
• TSUKAMOTO K, TANGIRALA R, CHUN SH, PURE E, RADER DJ: Rapid regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein E in apoE deficient mice. Arterioscler. Thromb. Vase. Biol. (1999) 19:2162–2170.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, HASTY AH, MAJOR AS et al.: Isoform-specific effects of apolipoprotein E on atherogenesis: gene transduction studies in mice. Circulation (2001) 104:2820–2825.
   PubMed Web of Science ®Google Scholar
• KIM IH, JOZKOWICZ A, PIEDRA PA,OKA K, CT-JAN L: Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl Acad. Sci. USA (2001) 98:13282–13287.
   PubMed Web of Science ®Google Scholar
• RINALDI M, CATAPANO AL, PARRELLA P et al: Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. Gene Ther. (2000) 7:1795–1801.
   PubMed Web of Science ®Google Scholar
• HARRIS JD, SCHEPELMANN S, ATHANASOPOULOS T et al.: Inhibition of atherosclerosis in apolipoprotein-E deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Ther. (2002) 9:21–29.
   PubMed Web of Science ®Google Scholar
• ATHANASOPOULOS T, OWEN JS, HASSALL D et al: Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice. Hum. Md. Genet. (2000) 9:2545–2551.
   PubMed Web of Science ®Google Scholar
• GOUGH PJ, RAINES EW: Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood (2003) 101:485–491.
   PubMed Web of Science ®Google Scholar
• MAHLEY RW, HUANG Y, RALL SC JR: Pathogenesis of Type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J. Lipid Res. (1999) 40:1933–1949.
   PubMed Web of Science ®Google Scholar
• TAGALAKIS AD, GRAHAM IR, RIDDELL DR, DICKSON JG, OWEN JS: Gene correction of the apolipoprotein (Apo) E2 phenotype to wild type ApoE3 by in situ chimaeraplasty. J. Biol. Chem. (2001) 276:13226–13230.
   PubMed Web of Science ®Google Scholar
• FUNKE H: Genetic determinants of highdensity lipoprotein levels. Curr. Opin. Lipidol (1997) 8:189–196.
   PubMed Web of Science ®Google Scholar
• WEBB NR, DE BEER MC, VAN DER WETHUYZEN DR et al.: Adenoviral vector-mediated overexpression of serum amyloid A in apoA-I-deficient mice. J. Lipid Res. (1997) 38:1583–1590.
   Google Scholar
• BENOIT P, EMMANUEL F, CAILLAUD JM et al.: Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation (1999) 99:105–110.
   PubMed Web of Science ®Google Scholar
• TANGIRALA RK, TSUKAMOTO K, CHUN SH, USHER D, PUREE, RADER DJ: Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation (1999) 100:1816–1822.
   PubMed Web of Science ®Google Scholar
• BELALCAZAR LM, MERCHED A, CARR B et al.: Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation (2003) 107:2726–2732.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TSUNODA T, TUZCU EM et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. /AMA (2003) 290:2292–2300.
   PubMed Web of Science ®Google Scholar
• NG DS, FRANCONE OL, FORTE TM, ZHANG J, HAGHPASSAND M, RUBIN EM: Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and upregulation of scavenger receptor class B Type I. J. Biol. Chem. (1997) 272:15777–15781.
   PubMed Web of Science ®Google Scholar
• MERTENS A, VERHAMME P, BIELICKI JK et al.: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation (2003) 107:1640–1646.
   PubMed Web of Science ®Google Scholar
• HOBBS HH, RADER DJ: ABC1: connecting yellow tonsils, neuropathy, and very low HDL. j Clin. Invest. (1999) 104:1015–1017.
   PubMed Web of Science ®Google Scholar
• MARCIL M, BROOKS-WILSON A, CLEE SM et al.: Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet (1999) 354:1341–1346.
   PubMed Web of Science ®Google Scholar
• AIELLO RJ, BREES D, BOURASSA PA et al.: Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterthscler. Thromb. Vase. Biol. (2002) 22:630–637.
   PubMed Web of Science ®Google Scholar
• VAN ECK M, BOS IS, KAMINSKI WE et al.: Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl Acad. Sci. USA (2002) 99:6298–6303.
   PubMed Web of Science ®Google Scholar
• HAGHPASSAND M, BOURASSA PAK, FRANCONE OL, AIELLO RJ: Monocyte/ macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. (2001) 108:1315–1320.
   PubMed Web of Science ®Google Scholar
• BASSO F, FREEMAN L, KNAPPER CL et al: Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J. Lipid Res. (2003) 44:296–302.
   PubMed Web of Science ®Google Scholar
• JOYCE C, AMAR MJ, LAMBERT G et ell.:The ATP binding cassette transporter Al (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Nat. Acad. Sci. USA (2002) 99:407–412.
   Google Scholar
• MCGOVERN MM, POHL-WORGALL T, DECKELBAUM RJ et al: Lipid abnormalities in children with types A and B Niemann Pick disease. J. Pediatr. (2004) 145:77–81.
   PubMed Web of Science ®Google Scholar
• CHOI HY KARTEN B, CHAN T et al.: Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease./ Biol. Chem. (2003) 278:32569–32577.
   Google Scholar
• MIRANDA SR, ERLICH S, FRIEDRICH VL JR, GATT S, SCHUCHMANN EH: Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther. (2000) 7:1768–1776.
   PubMed Web of Science ®Google Scholar
• JIN HK, SCHUCHMANN EH: Ex vivo gene therapy using bone marrow derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Md. Ther. (2003) 8:876–885.
   PubMed Web of Science ®Google Scholar
• BARBON CM, ZIEGLER RJ, LI C et al.: AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Md. Ther. (2005) (In Press).
   Google Scholar
• GORDON DA: Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Cuff. Opin. Lipidol. (1997) 8:131–137.
   PubMed Web of Science ®Google Scholar
• TIETGE UJ, BAKILLAH A, MAUGEAIS C, TSUKAMOTO K, HUSSAIN MM, RADER DJ: Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J. Lipid Res. (1999) 40:2134–2139.
   PubMed Web of Science ®Google Scholar
• GRAF GA, YU L, LI WP et ell.: ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. (2003) 278:48275–48282.
   Google Scholar
• WU JE, BASSO F, SHAMBUREK RD et al.: Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J. Biol. Chem. (2004) 279:22913–22925.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, YAMADA S, YAMAMOTO K et al.: Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation (1998) 98:1898–1904.
   PubMed Web of Science ®Google Scholar
• FRANKS, GAUSTER M, STRAUSS J, HRZENJAK A, KOSTNER GM: Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo. Gene Ther. (2001) 8:425–430.
   PubMed Web of Science ®Google Scholar
• VEERKAMP MJ, DE GRAAF J, HENDRIKS JC, DEMACKER PN, STALENHOEF AF: Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation (2004) 109:2980–2985.
   PubMed Web of Science ®Google Scholar
• PAJUKANTA P, LILJA HE, SINSHEIMER JS et al: Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat. Genet. (2004) 36:371–376.
   PubMed Web of Science ®Google Scholar